Étiquette : psychedelics

Lysergic Acid Diethylamide and Psilocybin Revisited, Mark A. Geyer, 2015

Lysergic Acid Diethylamide and Psilocybin Revisited Mark A. Geyer Biological Psychiatry, 2015, Volume 78, Issue 8, 544-553 https://doi.org/10.1016/j.biopsych.2015.08.003   The past decade brought the beginnings of a renaissance in research on psychedelic drugs. Two articles in this issue of Biological Psychiatry signify that the resurrection of this long ignored topic has begun to mature and bear at least the promise of fruit. In the early 1970s, the onset of the “War on Drugs” brought with it a near-total hiatus in serious research on psychedelic drugs, especially in the United States. The resumption of credible work in this area has come from Switzerland, where many of [...]

Lire la suite

The “Endless Trip” among the NPS Users : Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review, Laura Orsolini et al., 2017

The “Endless Trip” among the NPS Users : Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review Laura Orsolini, Gabriele Duccio Papanti, Domenico De Berardis, Amira Guirguis, John Martin Corkery and Fabrizio Schifano Frontiers in Psychiatry, 2017, Vol. 8, article 240 doi: 10.3389/fpsyt.2017.00240   Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, cannabis, methylenedioxy-methamphetamine (MDMA), psilocybin, mescaline, and psychostimulants. The recent emergence of novel psychoactive substances (NPS) posed a critical concern regarding the new onset of psychiatric symptoms/syndromes, including cases [...]

Lire la suite

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors, Roland R. Griffiths et al., 2017

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors Roland R. Griffiths, Matthew W. Johnson, William A. Richards, Brian D. Richards3, Robert Jesse, Katherine A. MacLean, Frederick S. Barrett, Mary P. Cosimano and Maggie A. Klinedinst Journal of Psychopharmacology, 2017, 1–21 DOI: 10.1177/0269881117731279   Abstract Psilocybin can occasion mystical-type experiences with participant-attributed increases in well-being. However, little research has examined enduring changes in traits. This study administered psilocybin to participants who undertook a program of meditation/spiritual practices. Healthy participants were randomized to three groups (25 each): (1) very [...]

Lire la suite

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personnality domain of openness, Katherine A. MacLean, Matthew W. Johnson and Roland R. Griffiths, 2011

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personnality domain of openness Katherine A. MacLean, Matthew W. Johnson and Roland R. Griffiths Journal of Psychopharmacology, 2011, 25, (11), 1453-1461. doi: 10.1177/0269881111420188.   Abstract A large body of evidence, including longitudinal analyses of personality change, suggests that core personality traits are predominantly stable after age 30. To our knowledge, no study has demonstrated changes in personality in healthy adults after an experimentally manipulated discrete event. Intriguingly, double-blind controlled studies have shown that the classic hallucinogen psilocybin occasions personally and spiritually significant mystical experiences that predict longterm changes in behaviors, attitudes and values. In [...]

Lire la suite

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later, Roland R. Griffiths et al., 2008

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later Roland R. Griffiths ,W.A. Richards , Matthew W. Johnson, Una D. McCann, R. Jesse Journal of Psychopharmacology, 2008, 1–12. Doi : 10.1177/0269881108094300   Abstract Psilocybin has been used for centuries for religious purposes; however, little is known scientifically about its long-term effects. We previously reported the effects of a double-blind study evaluating the psychological effects of a high psilocybin dose. This report presents the 14-month follow-up and examines the relationship of the follow-up results to data obtained at screening and on drug session days. Participants were 36 hallucinogen-naïve adults [...]

Lire la suite

Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers, Matthew W. Johnson et al., 2012

Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers Matthew W. Johnson, R. Andrew Sewell, and Roland R. Griffiths Drug and Alcohol Dependence, 2012, 123, (1-3), 132–140. doi: 10.1016/j.drugalcdep.2011.10.029   Abstract Background—Psilocybin is a well-characterized classic hallucinogen (psychedelic) with a long history of religious use by indigenous cultures, and nonmedical use in modern societies. Although psilocybin is structurally related to migraine medications, and case studies suggest that psilocybin may be efficacious in treatment of cluster headache, little is known about the relationship between psilocybin and headache. Methods—This double-blind study examined a broad range of psilocybin doses (0, 5, 10, 20, and 30 mg/70 kg) on headache in [...]

Lire la suite

The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonnance imaging environment : a preliminary investigation of tolerability, Robin L. Carhart-Harris et al., 2010

The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonnance imaging environment : a preliminary investigation of tolerability Robin L. Carhart-Harris et al., Journal of Psychopharmacology, 2010, 1-6 DOI: 10.1177/0269881110367445   Abstract This study sought to assess the tolerability of intravenously administered psilocybin in healthy, hallucinogen-experienced volunteers in a mock-magnetic resonance imaging environment as a preliminary stage to a controlled investigation using functional magnetic resonance imaging to explore the effects of psilocybin on cerebral blood flow and activity. The present pilot study demonstrated that up to 2 mg of psilocybin delivered as a slow intravenous injection produces short-lived but typical drug effects that [...]

Lire la suite

Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis, Robin L. Carhart-Harris et al., 2012

Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis Robin L. Carhart-Harris, Robert Leech, David Erritzoe, Tim M. Williams, James M. Stone, John Evans, David J. Sharp, Amanda Feilding, Richard G. Wise, and David J. Nutt Schizophrenia Bulletin, 2012 doi: 10.1093/schbul/sbs117   model of psychosis. This study measured the effects of psilocybin on resting-state network and thalamo-cortical functional connectivity (FC) using functional magnetic resonance imaging (fMRI). Fifteen healthy volunteers received intravenous infusions of psilocybin and placebo in 2 task-free resting-state scans. Primary analyses focused on changes in FC between the default-mode- (DMN) and task-positive network (TPN). Spontaneous activity in the DMN is orthogonal [...]

Lire la suite

Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study, Alicia L. Danforth, Charles S. Grob et al., 2018

Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults : a randomized, double-blind, placebo-controlled pilot study Alicia L. Danforth, Charles S. Grob, Christopher Struble, Allison A. Feduccia, Nick Walker, Lisa Jerome, Berra Yazar-Klosinski & Amy Emerson Psychopharmacology, 2018, https://doi.org/10.1007/s00213-018-5010-9   Abstract Rationale : Standard therapeutic approaches to reduce social anxiety in autistic adults have limited effectiveness. Since 3,4- methylenedioxymethamphetamine (MDMA)-assisted psychotherapy shows promise as a treatment for other anxiety disorders, a blinded, placebo-controlled pilot study was conducted. Objectives : To explore feasibility and safety ofMDMA-assisted psychotherapy for reduction of social fear and avoidance that are common in the autistic population. Methods : Autistic adults with marked to [...]

Lire la suite

Psychedelic therapy for smoking cessation : Qualitative analysis of participant accounts, Tehseen Noorani, Albert Garcia-Romeu, Thomas C. Swift, Roland R. Griffiths and Matthew W. Johnson, 2018

Psychedelic therapy for smoking cessation : Qualitative analysis of participant accounts Tehseen Noorani, Albert Garcia-Romeu, Thomas C. Swift, Roland R. Griffiths and Matthew W. Johnson Journal of Psychopharmacology, 2018, 1 –14 https://doi.org/10.1177/0269881118780   Abstract Background : Recent pilot trials suggest feasibility and potential efficacy of psychedelic-facilitated addiction treatment interventions. Fifteen participants completed a psilocybin-facilitated smoking cessation pilot study between 2009 and 2015. Aims : The aims of this study were as follows: (1) to identify perceived mechanisms of change leading to smoking cessation in the pilot study; (2) to identify key themes in participant experiences and long-term outcomes to better understand the therapeutic process. Methods : Participants were [...]

Lire la suite